Biotechnology company BioAtla, Inc. (BCAB) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types.ADC is a promising treatment modality with broad applicability across multiple tumor indications.

生物技术公司BioAtla，Inc.（BCAB）周一宣布，美国食品和药物管理局（FDA）已批准其研究性新药（IND）申请，以评估BA3361（CAB-Nectin-4）抗体-药物偶联物（ADC）治疗多种肿瘤类型。ADC是一种有前途的治疗方式，在多种肿瘤适应症中具有广泛的适用性。

The CAB technology is designed to eliminate or reduce both on-target, off-tumor and off-target, off-tumor toxicities.BA3361, CAB-Nectin4-ADC, is a conditionally and reversibly active antibody drug conjugate directed against Nectin4, a cell-cell adhesion molecule overexpressed in multiple human malignancies..

CAB技术旨在消除或减少靶向，非肿瘤和非靶向，非肿瘤毒性。BA3361，CAB-Nectin4-ADC，是一种针对Nectin4的有条件且可逆活性的抗体-药物偶联物，Nectin4是一种在多种人类恶性肿瘤中过表达的细胞-细胞粘附分子。。

BA3361 is the first molecule containing one of BioAtla's novel NextGen ADC linkers with improved stability and tumor specific payload release. BA3361 showed superior activity in patient-derived pancreatic cancer xenograft models. For comments and feedback contact: editorial@rttnews.comBusiness News

BA3361是第一个含有BioAtla新型NextGen ADC接头之一的分子，具有改进的稳定性和肿瘤特异性有效载荷释放。BA3361在患者来源的胰腺癌异种移植模型中显示出优异的活性。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股